Horizon Scanning

Our estimates and analyses provide a validated foundation for assessing how much the Regions should appropriate for medicines in the future.

Danish Regions use the estimates in their annual negotiations with the Government on finances and the individual Regions apply them in their own budgets.

The estimates take account of increased costs of new, expensive medicines and possible savings, for example if there are cheaper biosimilar medicines on the market.

Among other things, we use data from the European Medicines Agency (EMA)  and supplement this with knowledge from commercial databases and selected newsletters from throughout the world.

Another source of information is pipeline meetings with pharmaceutical companies. These give us in-depth knowledge about the products they are planning to market in the years to come.

Moreover, we participate in both national and international conferences and networks. We do this in order to be at the forefront of developments and to keep up to date with the most recent knowledge in the area.